Файловый архив студентов. Файловый архив студентов.
1262 вуза, 4625 предмета.
/ Регистрация
FAQ Обратная связь Вопросы и предложения
Добавил:
kiopkiopkiop18@yandex.ru Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Ростовский Государственный Медицинский Университет
Предмет:
Медицина общая
Файл:

6 курс / Медицинская реабилитация, ЛФК, Спортивная медицина / Физиотерапия, лазерная терапия / Ингаляционная_небулайзерная_терапия_заболеваний_респираторной_системы

.pdf
Скачиваний:
1
Добавлен:
24.03.2024
Размер:
48.72 Mб
Скачать
☆

Список литературы

1.Геппе Н.А., Петровский Ф.И. Пульмикорт - суспензия при

бронхиальной

астме у детей - больше чем просто хор о ­

шее

средство

в ряду многих.//Атмосф ера. Пульмоноло­

гия

и аллергология. - 2007. - № 1. - С .17-22.

2. Геппе Н.А.,

Малышев В.С.# Лисицин М.Н., С еливерсто­

ва Н. А. и

др.

Бронхоф онограф ия

в комплексной д иа ­

гностике

бронхиальной астмы у

детей.// Пульмоноло­

гия. - 2002. - V ol.12. - № 5. - С .33-39.

3.Геппе Н.А., Батырева О.В., Малышев B.C., Утюш ева М.Г., Старостина Л.С. Волнообразное течение бронхиальной астмы у детей. Терапия обострений.//Трудный пациент. - 2007 - № 2.

4.Геппе Н.А., Малахов А.Б. Муколитические и противокаш - левые средства в практике педиатра (лекция).// Детский доктор. - 1999. - № 4. - С. 42-45.

5.Геппе Н.А., Мокина Н.А. Санаторная помощь в проф и ­ лактике инвалидности у детей с бронхиальной астмой. -

М.: Ф армарус Принт, 2007. - 232 с.

6.Глобальная стратегия лечения и проф илактики

бронхиальной астмы / Под ред. академика РАМН

А.Г. Чучалина: Т.1, 2. - 1997.

7.Гусейнов А.А., Айсанов З.Р., Чучалин А.Г. Акустический анализ дыхательных звуков; состояние вопроса//П ульмонология. - 2005. - № 6. - С .105-112.

8.Егорова В.Б. Диагностическое значение компьютерной

бронхоф онограф ии при заболеваниях органов дыхания

у новорожденных: Автореф . диссертации. - М., 2006.

9.Капранов Н.И., Каширская Н.Ю., Симакова О.И. и др. Муковисцидоз: современные достижения и проблемы.: Методические рекомендации. - М., 1997.

10.Коровина Н.А., Захарова И.Н., Заплатников А.Л., О всян­ никова E.M. Кашель у детей. Противокашлевые и отхар­ кивающие лекарствен-ные средства в педиатрической практике: Пособие для врачей. - М.: Посад, 2000. - 53 с.

11.

Ларю ш кина P.M., Р ы б к и н А.И., Решетова Т.Г. и др. Э ф ­

 

ф ективность Лазолвана в терапии атопической бронхи­

 

альной астмы .// Современные проблемы педиатрии: Ма­

 

тер. VIII съезда педиатров России. - М., 1998. - № 32.

12.

Лукина О. Ф. Современные методы исследования ф унк­

 

ции легких у детей .//Л ечащ ий врач - 2003. - № 3.

Список литературы

13. Малышев B.C., Ардаш никова С И ., Каганов СЮ . и др .//

Способ регистрации дыхательных ш умов..// Бюллетень изобретений. Патент РФ № 5062396. - 1995. - №18.

14.Методические указания по дезинф екции, предстерилизационной очистке и стерилизации изделий медицинс­ кого назначения. - М., 2000.

15.Мещеряков В.В., Титова Е.Л., Блохина О.П Способ лече­ ния бронхиальной астмы.// Бюллетень изобретений. Па­ тент РФ № 2161907. - 2001. - №2.

16.Мещеряков В.В., Титова Е.Л. Объективный критерий длительности комбинированной базисной терапии при бронхиальной астме у д е те й / / Вопросы практической пе­ диатрии. - 2007, №6. - с. 5-9.

17.Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». - М., 2006г.

18.Огородова Л.М., Петровский Ф .И., Деев И.А. Средства ингаляционной доставки препаратов: взгляд врача и взгляд пациента.//Атм осф ера. Пульмонология и аллер­ гология. - 2002. - № 1 ( 4 ) . -С 16-19.

19. Самсыгина Г.А., Зайцева О.В., Корнюш ин М.А. Бронхиты

у детей. Отхаркивающая и муколитическая терапия. -

М., 1999.

20.Царькова С.А., Абелевич М.М. Небулизированный будесонид (суспензия Пульмикорта) при острой обструкции

дыхательных путей.// Педиатрическая ф армакология. -

2 0 0 3 .-Т. 1. - № 2. - С 36.

21.Agency for Healthcare Policy and Research. Acute pain man­ agement, operative or medical procedures and trauma 92-0032. Clinical practice guideline. Rockville, Maryland, USA, Agency for Healthcare Policy and Research Publications, 1992.

22.A gertoft L, Pedersen S. Effect of long-term treatm ent with

inhaled

budesonide on adult

height

in children with asth­

m a .//N. Engl. J. Med., 2000 Oct 12; 343(15): 1064-1069.

23. A gertoft

L,

Andersen A., Weibull

E.,

Pedersen

S. Systemic

availability

and pharmacokinetics

of

nebulised

budesonide

in preschool children .//A rch .

Dis.

Child., 1999

Mar; 80(3):

241-247.

24.Anbever R., Mintzes J.D.,Wang J . , et al. Formulation and physical characterization of large porous particles for inha­ lation.//Pharm . Res. (1999) I 16:1735-1742.

70Список литературы

25.Anhoj J . , ThotTson L, Bisgaard H., The systemic exposure of budesonide inhaled from a metal spacer is similar in young children and adults.//Eur RespirJ . , 1998: 12 SuppL 28:378 s.

26.Anion S., Grigg J . , Silverman M. Effectiveness of budesonide

aerosol in ventilator dependent preterm babies: a prelim i­

nary report.//P aediatr Pulmonol, 1996: 21: 231-235.

27.Asthma insights and reality in Europe: AIRCEE, Russia, Final Report 2001. [Электронный ресурс]. - Электрон, дан. - Ре­

жим доступа: http://209.43.39.198/aire/aire-tell.cfm

28.Ausejo М., Saenz A., Pham В., Kellner J.D ., Johnson D.W.,

Moher D.f Klassen T.P. G lucocorticoids for croup (Cochrane

Review). In: The Cochrane Library. Issue 2. O xford: Update

Software, 2001.

29.Barry P.W., O 'Callaghan C. The Output of Budesonide from

Nebulisers, Proceedings of the Aerosol Society Meeting

«Drug Delivery to the Lungs VI». London, 1996.

30.Bauer K.H., Froemming K.H., Fuehrer C. Lehrbuch der pharmazeutischen technologie . Mit einer Einfuehrung in die Biopharmazie. W issenschaftliche Verlagsgesellschaft mbH, Stuttgart, Germany (2002).

31.Berdel D. Die «Nationale Versorgungs-Leitlinie Asthma bronchiale», paediatrischer.//Teil, in: Zeitschrift der Gesellschaft fuer Paediatrische Pneumologie, 2004; 45-54.

32.Bisgaard H.What drives prescription patterns in pediatric

asthma m anagem ent?.// J Allergy Clin Immunol., 2007 Jul

14; [Epub ahead of print].

33.Boe J . , Dennis J . H ., O'Driscoll B.R. European Respiratory So­ ciety Nebuliser Guidelines: Clinical Aspects.// Eur Respir Rev, 2000; 10: 76, 495-583

34.Boe J . , Dennis J.H . European Respiratory Society Nebuliser Guidelines: Technical Aspects.// Eur Respir Rev, 2000; 10: 72, 1-237.

35.Bowton D.L., Goldsmith W.M., Haponik E.F. Substitution of

metered dose inhalers for hand held nebulisers: success and

cost savings in a large acute care hospital.//C hest, 1992; 101:

305-308.

36.Boychuk R.B., Demesa C .J ., Kiyabu K.M., et al. Change in approach and delivery of medical care in children with asth­ ma: results from a multicenter em ergency departm ent edu ­

cational asthma m anagem ent

program .// Pediatrics., 2006

Apr; 117(4 Pt 2): S. 145-151.

 

 

 

37. Brambilla G.,

Ganderton D.,

Garzia R., LEWIS D., Meakin

B., Ventura P.

M odulation of

aerosol

clouds produced

by

pressurized inhalation aerosols.// Int. J.

Pharm., 1999;

186:

53-61.

 

 

 

 

38.Callahan S., Canny G., Lcvison H. I Efficacy of frequent nebu­

lised ipratropium bromide added to frequent high-dose a l­

buterol therapy in severe childhood asthm a.// Pediatr, 1995;

126:639-645.

39.Calverley P., Pauwels Dagger R., Lofdahl C.G., etal. Relationship between respiratory symptoms and medical treatment in exac­ erbations of COPD.//EurRespir J . , 2005 Sep., 26(3): 406-413.

40.C am argoC .A ., Patel P., M cLaughlinT., Leibman C. Budesonide

 

inhalation suspension (bis) reduces

risk of recurrent em er­

 

gency

departm ent

(ED) visits

or hospitalization in asthmatic

 

children .//A bstract

presented

at ATS

annual meeting 2004.

 

[Электронный ресурс]. - Электрон, дан. - Режим доступа:

 

http://w w w .thoracic.ora.

 

 

 

41.

Carroll

K .N ., G ebretsadik Т.,

Griffin

M.R., et al.

Maternal

 

asthma and maternal smoking are associated with increased

 

risk of

bronchiolitis

during infancy.//

Pediatrics., 2007 Jun;

 

119(6): 1104-1112.

 

 

 

 

42.

Cates C .J. Holding

chambers versus nebulisers for beta a g o ­

 

nist treatm ent of

acute asthma (Cochrane Review).

In: The

 

Cochrane Library.

Issue I. Oxford: Update Software;

1999.

43.Christie G.L., Helms P.J., Godden D.J., et al. Asthma, wheezy

bronchitis, and

atopy across two generations.//Am J. Respir

C ritC are Med.,

1999 Jan; 159(1): 125-129.

44. Chua H.L., Col Ms G.G., Newhur A.M., et al. The influence of age on aerosol deposition in children....// Eur Respir J . , 1994;

7:2185-2191.

45.Cipolla D., ClarkA ., Chan H., Gonda I., Shire S. Assessment of aerosol delivery systems for recom binant human deoxyribo­ nucleic.//S TP Pharma.Sci., 1994; 4: 50-62.

46. Cloutier M.M. Nebulised steroid therapy in bronchopulm o­

nary dysplasia.//Pediatr Pulmonol, 1993; 15: 111-116.

47.Collis G.G., Cole C.H., Le Souef P.N. Dilution of nebulised

aerosols by air entrainm ent

in

children.// Lancet, 1990;

336:

341-343.

 

 

 

48. Crom pton G. A brief history

of

inhaled asthma therapy

over

the last fifty years.//Prim Care Respir J . , 2006 Dec;15(6): 326-

331.Epub 2006 Nov 7.

49.Den jean A., Paris-Llado J . , Zupan V., et al. Inhaled salbutamol and beclomethasone for preventing bronchopulm onary dysplasia: a random ized double-blind study.// Eur J. Pediatr, 1998; 157: 926-931.

50.Dennis J.H .,S tenton S. C., Beach J .R ., Avery A. J. .Walters E. H., Hendrick D.J., Jet and ultrasonic nebuliser output: use of a new method for direct measurement of aerosol output.// Thorax, 1990, 45: 728-732.

51. Dennis J.H . Drug Nebuliser Design and Performance: Breath

64.

Enhanced Jet Vs Constant Output Jet Vs U ltrasonic.//Journal of Aerosol Medicine, 1995; 8: 277-280.

52.Dolovieh М., Ryan G., Newhouse M.T. Aerosol penetration into the lung: influence on airway responses.// Chest, 1981;

80:834-836.

53. Ducharme

F.M., Davis G.M. Randomized controlled trial of

65.

ipratropium

brom ide

and

frequent low doses of salbutamol

 

in the managem ent

of

mild to m oderate acute pediatric

6 6

asthm a.//Pediatr, 1998; 133:479-485.

 

54.Durand D., Clyman R., Heymann A., et ah. Effects of a pro­

tein-free, synthetic surfactant on survival and pulmonary

67.

function in preterm lam bs.//Pediatr, 1985; 107(5): 775-780.

55.Edwards C.A., Osman L.M., Godden D.J., Douglas J.G .

 

Wheezy bronchitis in childhood: a distinct

clinical

entity

 

 

with lifelong significance?.//C hest.,

2003 Jul; 124(1): 18-24.

 

56.

Ehtezazi Т., Horsfield

M.A., Barry

P.W.,

O'Callaghan

C. Dy­

6 8 .

 

namic change

of the

upper airway during

inhalation via

 

 

aerosol delivery devices.// J. Aerosol

Med.,

2004

Winter;

 

 

17(4): 325-34.

 

 

 

 

 

 

 

57.

Ferguson B.J., Paramaesvaran S.,

Rubinstein

E. A study of

69.

 

the effect of nasal steroid sprays in perennial allergic rhinitis

 

 

patients with

rhinitis

m edicam entosa.//

O tolaryngol.

Head

 

 

N eckSurg, 2001 Sep; 125(3): 253-260.

 

 

 

70.

58.Fink J. Aerosol device selection: evidence to practice.// Respir. Care, 2000; 45(7): 874-885.

59.

Finlay W.,

Stapleton

K.

Under sizing of

droplets

from

a

71.

 

vented nebuliser caused by aerosol heating during

transit

 

 

through an

Anderson

im pa ctor.//J . Aerosol Sci,

1999;

30:

 

 

105-109.

 

 

 

 

 

 

 

 

60.

Finlay W.,

Lange C,

King М., Speert D.

Lung

delivery

of

72.

 

aerosolized

dextran.// Am

J. Resp. Crit.

Care Med., 2000;

 

 

161:91-97.

 

 

 

 

 

 

 

 

61.Finlay W., Stapleton K., Zuberbuler P. Predicting lung dos­

 

age of a nebulised suspension: Pulmicort (budesonide).//

 

 

Part. Sci. Tech., 1997; 15: 243-251.

 

 

73.

62.

Fitzgerald D.,

Mel Ms C, Johnson М., Allen H.,

Cooper P., van

 

 

Asperen P. Nebulized budesonide is as effective as nebulized

 

 

adrenaline in

moderately severe croup .// Pediatrics,

1996;

74.

 

97: 722-7255;

1999; 54: 961-967.

 

 

 

63.

Frederiksen B.f Koch C, Hoiby N. A ntibiotic treatm ent of ini­

 

 

tial colonization with Pseudomonas aeruginosa postpones

 

 

chronic infection and prevents deterioration

of pulm onary

75.

 

function in cystic fibrosis.// Pediatr Pulmonol,

1997; 23:

330-

 

 

335.

 

 

 

 

Список литературы

Fuchs H.J., Borowitz D.S.,

Christiansen

D.H., Morris E.M.,

Nash M.L, Ramsey B.W., Rosenstein B.J., Smith A.L., Wohl

M.E. Effect of

aerosolized

recom binant

human

DNase on

exacerbations

of respiratory

symptoms

and

on

pulm onary

function in patients

with cystic fibrosis.// N.

Engl. J. Med.,

1994; 331: 637-642.

 

 

 

 

 

Global Strategy for

Asthma

M anagem ent

and

Prevention

(GINA) 2006.

 

 

 

 

 

 

Godden C.W., Campbell M.J., Hussey М., Cogswell J . J . D ou­

ble blind placebo controlled

trial of

nebulised budesonide

for croup .//A rch

Dis Child,

1997; 76:

155-158; 448-456.

 

G oggin

N.,

Macarthur C,

Parkin P.C.

Randomized trial of the

addition

of

ipratropium

brom ide to

albuterol

and

cortico ­

steroid therapy in children hospitalized

because of an

acute

asthma

exacerbation.//

Arch

Pediatr

Adolesc

Med,

2001;

155(12): 1329-1334.

 

 

 

 

 

 

 

 

 

 

 

Groenberg S.,

Magnusson P., Bladh N. Chemikal com patibil­

ity of

budesonide inhalation

suspension (Pulm ikort

respuls)

with other

nebulisation

products.// Am erican

Jurn.

Respir.

Crit. Care med.,

2001; 163 (№5); A 558.

 

 

 

 

 

 

 

Harriman A.,

Pursel N.,

 

Fleming S.

Can

we

mix

nebuliser

solutions? Stability of drug admixtures in

solutions

for

nebulisation.//Pharm . Pract., 1996; 6 (9): 347-348.

 

 

 

 

H igenbottam

T.

Pulmonary

hypertension

and

chronic

o b ­

structive

pulm onary disease: a case for treatm ent. /

Proc Am

Thorac

Soc. 2005;2(1 ):12-9.

 

 

 

 

 

 

 

 

 

H usbyS ., A g e rto ft L, Mortensen S.,

Pedersen S. Treatm ent

of croup with nebulised steroid (budesonide): a

double

blind,

placebo

controlled

stud y .//A rch

Dis Child,

1993;

68:

352-35 5.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hubner

М.,

Hochhaus G.,

D erendorf

H. Comparative

phar­

m acology,

bioavailability,

pharm acokinetics,

and

 

pharm a­

codynamics of inhaled glucocorticosteroids.//

Im m unology

and A llergy

Clinics of North

America.

-

2005. - Vol.

25. -

P. 469-488.

Hvizdos K.M., Jarvis B. Budesonide inhalation suspension.

Areview of its use in infants, children and adults with inflam ­

matory respiratory disorders.//D rugs, 2000; 60: 1141-1478.

Janssens H., De Jongste J . , Fokkens W.,

Robben S., W out-

ers K., Tiddens H. The Sophia anatom ical

infant nose-throat

(saint) model: a valuable tool to study aerosol deposition in infants.//A erosol Med., 2001; 14: 433-441.

Janssens H., Heijnen E., De Jong V., et al. Aerosol delivery from spacers in wheezy infants: a daily life study.// Eur. Respir.J., 2000; 16:850-856.

Список литературы

 

 

 

 

76.

Jauernig J . , Ohl S., Knoch М.,

Keller M. Effects of the test

 

set-up

form ulation, and

nebuliser type

on

aerodynamic

 

droplet

characteristics.

Proceedings of the

Respiratory

 

Drug Delivery DC. Palm Desert,

CA, USA, (2004): 609-612.

77.

Jauernig J . , Ohl S., Luber М.,

Keller M. Differences in re­

 

sults obtained with the next generation

impactor (NGI) for

 

Pulmicort suspension and according to the CEN standard

 

EN13544-1

fo ra NaF-Solution. Proceedings of the Drug De­

 

livery to the

Lungs XIV London,

UK (2003): 41-44.

78.Johnson D.W., Jacobson S., Hadiicld P., Mundy M.E., Schuh S. A comparison of nebulised budesonide. intramuscular dexamcthasone. and placebo for moderate to severe croup.// N. Engl. J. Med., 1998; 339: 498-503.

79.Keller М., Balcke A., Tservistas М., et al. Reduced treatment

time for tobramycin application by device and form ulation customization. Proceedings of the 17th Annual North Am er­ ican Cystic Fibrosis Conference, Anaheim, CA, USA (2003).

80.Keller М., Jauernig J . , Schueepp K., et al. Using infant depo­ sition models to improve inhaler system design. Proceedings of the Respiratory Drug Delivery IX, Palm Desert, CA, USA (2004): 221-231.

81.Keller М., Jauernig J . , Knoch M. Nebuliser nanosuspensions:

important device and form ulation interaction. Proceed­

ings of the Respiratory Drug Delivery VIII. Tucson, AZ, USA

(2002): 197-206.

82.Keller М., Mueller-Walz R., Gilchrist P., Lefrancoise G., Haeberun B. Effects of storage on the in-vitro performance of

form oterol-fum arate

powder blends

in

the Skyepharma

MDPI. Proceedings of the Respiratory

Drug

Delivery VII. Tar­

pon Springs, Florida,

USA (2000): 511

-514.

 

83.Keller M. Innovations and perspectives of metered dose inhalers

in pulmonary drug delivery.//Ink J. Pharm., 1999; 186: 81-90.

84. Kemp J ., Turck

C .J.,

York J.M . Evaluation

of albuterol

1.25 mg

and

0.62

mg

for

mobilization in 6- to

12-year-old

children

with

moderate to

severe asthma.//Adv.

Ther., 2007

May-Jun; 24(3): 463-477.

85.Kemp J. Is there a best outcome measurement for patients with asthma?.// Ann. Allergy Asthma Immunol., 2006 Oct; 97(4): 432-439.

86.Khine H., Fuchs S.М., SavilleA.L. Continuous vs intermittent

nebulised albuterol for emergency management of asth­

ma.//Asad. Emerg. Med., 1996; 3: 1019-1024.

87.Kikuchi K., Watanabe М., Hashizume T. и соавтУ/New clas­ sification and analysis of Lung ounds.- Nippon Kyobu Geka Gakkai Zasshi. - 1989 Dec. - Vol. 37(12). - P.2532-2537

88.KlassenT.P., CraigW.R., MoherD., Osmond M.H., Pasterkamp

H., S utcliffeT ., Watters L.K., Rowe P.C. Nebulized budesonide and oral dexamethasone for treatm ent of croup. A randomized controlled trial.//JAM A, 1998; 279: 1629-1632.

89.Klassen T.P., Sutcliffe Т., Watters L.K., Wells G.A., Allen U.D.,

Li M.M. Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized, controlled trial.// J Pediatr., 1997 Feb; 130(2): 170-172.

90.Klassen T.P., Watters L.K., Feldman M.E., Sutcliffe Т., Rowe

P.C. The efficacy of nebulised

budesonide in dexametha­

s o n e - treated outpatients with

croup.// Pediatrics., 1996

Apr; 97(4): 463-466.

 

91.KlassenT.P., CraigW.R., M oherD .etal. Nebulised budesonide

vs oral dexamethasone for treatment of croup: a random ­

ized controlled trial.//JAM A, 1998; 279: 1629-1632

92.Kling S., Gie R.P., Riphagen S. Dornase alpha in the man-

judgm ent of a mechanically ventilated infant with cystic fi­

brosis / LetterJ.//Pediatr Puhnonol, 1997; 24: 124-125.

93.Knoch М., Sommer E. Jet nebuliser design and function.// Eur. Respir. Rep., 2000; 10: 183-186.

94.Knoch М., Keller M. The customised electronic nebuliser: a new category of eiguiol aerosol drug delivery systems.// Ex­ pert Opin Drug Deliver, 2005; 2: 377-390.

95.LanesS.F., Garrett J. E ., Wentworth C.E., 3rd, Fitzgerald J .М.,

Karpel J.P. The effect of adding ipratropium bromide to salbutamol in the treatm ent of acute asthma: a pooled analysis of three trials.//Chest, 1998; 114(2): 365-372

96.Leflein J.G ., Szefler S .J., Murphy K.R., et al. Nebulised budesonide inhalation suspension compared with cromolyn sodium nebuliser solution for asthma in young children: Re­ sults of a Randomized Outcomes Trial.// Pediatrics. - 2002.1 Vol. 1 0 9 .-P. 866-872.

97.Lindemann H. Mukovoscidoze: Standardterpie und perspektiven.//Atemw. - Lungenfunk., Jargang 30, № 3/2004, s. 109-119.

98.Lodrup-Carlsen K.C., Nikander K., Carlsen K.H. How much nebulised budesonide reaches infants and toddlers?.//Arch Dis Child. - 1992. - Vol. 67. - P. 1077-1079.

99.Macdonald W.B., Geelhoed G.C. Management of childhood croup.//Thorax., 1997 Sep; 52(9): 757-759.

100.Maehara N., Uhea S., Mori E. Influence of the vibrating sys­

tem of a

m ultipinhole-plate ultrasonic nebuliser on

its peri

form ance.// Rev. Set. Instrum.,

1986; 57: 2870-2876.

 

101.Mallol J . ,

Rattray

S.,

Walker

G., Cook D., Robertson C.F.,

Aerosol deposition

in

infants

with cystic fibrosis.//

Pediatr.

Pulmonol.,

1996; 21: 276-281.

 

 

102.Matthews Е.Е., Curtis P.D., McLain В.I., et al. Nebulised budesonide versus oral steroid in severe exacerbations of child­ hood asthma.//Acta Paediatr. - 1999. - Vol. 88. - P. 841-843

103.Maurer A., Ollig U. Mukoviszidose: physiotherapie. Bonn, 1994.

104. Mecrt

K.L,

S arnaikA .P .,

Yelmini

M.J., Lieh-Lai M.W. Aero­

sol of

soil

ribavirin

in mechanically ventilated

children with

respiratory

syncytial

virus

lower

respiratory

tract disease:

A prospective, double-blind, randomized trial.// Civ. Care.

jMed.,

1994; 22: 566-572.

 

 

 

105.Mendelson L, Cook D., Cruz-Rivera М., Fitzpatricks., Smith J.A. Twice-daily budesonide inhalation suspension in infants and children < 4 and > or = 4 years of age with persistent asthm a.//J Asthma, 2002 May; 39(3): 227-237

106.Motoyama E.K., Fort M.D., Klesh K.W., Mutich R.L., Guthrie

R.D.

Early onset of airway reactivity in

premature infants

with

bronchopulmonary dysplasia.// Am.

Rev. Respir. Dis.,

1987 Jul; 136(1): 50-57.

107.Mukoviszidose: physiotherapie. Bonn, 1994.

108.Murphy K.R., Fitzpatrick S., Cruz-Rivera М., et al. Effects of budesonide inhalation suspension compared with cromolyn sodium nebulizer solution on health status and caregiver

quality of life in childhood asthma.// Pediatrics. - 2 0 0 3 .- Vol. 1 1 2 .-P. 212-219.

109.Newhouse М., Hirst P., Duddu S. et al. Inhalation of a dry powder tobramycin pulmosphere form ulation in healthy volunteers.//Chest, 2003; 124: 360-366.

110.Newman S. P.Spacer devices for metered dose inhalers./Clin Pharmacokinet. 2004; 43(6):349-60.

111.Newman S.P., Woodman G., Moren F., Clarke S.W. Bronchodilatory therapy with nebuhaler: how important is the delay between firing the dose and inhaling?.// Br. J. Dis. Chest.,

 

1988 Jul; 82(3): 262-267.

 

 

112.

Nikander

K., Berg E., Morra L, Smaldone G.C. In vitro test­

 

ing of inhalation devices with face masks.// Eur. Respir. J . ,

 

2001 .-V ol. 18: Suppl. 33 - P. 494s.

 

113.

Nikander

K., Turpeinen

М.,

Forsman R., W ollmer P. Jet and

 

ultrasonic

nebulisation

of

budesonide in young

children.//

 

J. Aerosol. Med.,

1993. - Vol. 6 (Suppl). - P. 71

 

114. Nivenr W.,

Speer

M.f Schreier H. Nebulisation of

liposomes

II. The effects of size and modelling of solute release pro­ files.//Pharm . Res., 1991; 8: 217-221

115.O'Callaghan C, Milner A.D., Swarbrick A. Nebulised sodium cromoglycale in infancy: airway protection after deterioration.//Aixh. Pis. Child., 1990; 65: 404-406.

Список литературы

116.O'Gallaghan C, Milner A.D., Swarbiek A. Paradoxical de­ terioration in lung function after nebulised salbutamol in

wheezy infants.//Lancet,

1986;

ii: 1424-1425

 

117. Olschewski H., Walmrath

D.,

Schermuly R.,

Ghofrani H.A.,

et al. Aerosolized prostacyclin

and iloprost in severe pulm o­

nary hypertension.//Ann. Intern. Med., 1996;

124: 820-824.

118.Paul K., Rietschel E., Ballmann М., etal. Effect of treatment with Dornase alpha on airway inflammation in patients with cystic fibrosis.//Am. J. Respir. Crit. Care Med., 2004; 169: 699-725.

119.Pedersen S. Clinical safety of inhaled corticosteroids for

asthma

in

children: an update of long-term trials.// Drug

Saf., 2006; 29(7): 599-612.

 

 

120. Principy

N.,

et al.

Possibility of interaction among antibiot­

ics and

mucolitics

in children .//Y nt. Y. Clinical

Pharmacol.

Res., 1986; 615, 369-372.

 

 

121. Pulmicort

International Product

Monograph.

AstraZen­

eca Product Strategy & Licensing,

SE-221 87 Lund, Sweden,

2002. - 278 p.

 

 

 

122. Rabe K.F., Adachi М., Lai C.K., et al. W orldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys.//J. Allergy Clin. Immunol., 2004.

-V ol. 114, № 1 .-P . 40-47.

123.Ramsey B.W., Pepe M.S., Quan J.M ., et al. Intermittent ad ­ ministration of inhaled tobramycin in patients with cystic

fibrosis.//N. Engl. J. Med., 1999; 340: 23-30.

124.Ratjen F., Doering G., Nikolaizik W.H. Effect of inhaled to ­ bramycin on early Pseudomonas aeruginosa colonization in patients with cystic fibrosis.//Lancet, 2001; 358: 983-84.

125.Respiratory therapy equipment - Pan 1: Nebulising systems and their components. European Committee for Standard­ ization (CEN), Brussels, Belgium (2001).

126.Riordan J.R., Rommens J.M ., Kerem B.S., et al. Identifikation of the cystic fibrosis gene: cloning and characterization of complementary DNA.//Science, 1989; 245: 1066-1073.

127.Rodrigo G., Rodrigo C, Burschtin O. A meta-analysis of the

effects of ipratropium

bromide in adults with acute asth­

ma. //Am . J. Med. 1999;

107(4): 363-370.

128.Rodrigo G.J., Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency de­ partment.// Am. J. Respir. Crit. Care Med., 2000; 161(6): 1862-1868.

129.Rudolph G.f Kobrich R., Stahlhofen W. Modeling and alge­ braic form ulation of regional aerosol deposition in m an.//J. Aerosol. S ci., 1990; 21: 5306-5406.

Соседние файлы в папке Физиотерапия, лазерная терапия
Помощь Обратная связь Вопросы и предложения Пользовательское соглашение Политика конфиденциальности